title: Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis.
abstract: OBJECTIVE
  Serum levels of leptin, the adipocyte-derived hormone regulating food intake and energy expenditure in mammals, have been found to be increased in cirrhotic patients. The aim of the present study was to investigate leptin serum level in relation to anthropometric features and liver function in patients with viral chronic hepatitis or liver cirrhosis.
  
  
  METHODS
  Serum leptin levels were determined by radioimmunoassay in 30 male and 10 female patients with chronic hepatitis, in 42 male and 10 female patients with liver cirrhosis, and in four respective control groups. Liver function was evaluated by the monoethylglycinexylidide formation test. Body mass index and body fat mass were estimated by weight, height and skinfold thickness measurements.
  
  
  RESULTS
  Compared with controls, absolute serum leptin levels were significantly (p<0.01) lower in chronic hepatitis patients and similar in cirrhotic patients. Leptin serum levels were significantly (p<0.05) higher in cirrhotic than in chronic hepatitis patients. When expressed in relation to body fat mass, the above differences persisted; however, cirrhotic females showed significantly (p<0.05) higher serum leptin values than controls. Serum leptin values correlated negatively (p<0.01) with monoethylglycinexylidide serum values in all groups of patients.
  
  
  CONCLUSIONS
  In patients with chronic viral liver disease, serum leptin levels tend to increase as liver function worsens. This may reflect a decline in the ability to downregulate energy expenditure as an adaptation to anorexia and/or to defective substrate utilisation due to liver disease and may negatively influence body weight homeostasis in these patients.
authors.affiliation: Department of Internal Medicine, University of Genoa, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Testa
authors.forename: R
authors.initials: R
authors.lastname: Franceschini
authors.forename: E
authors.initials: E
authors.lastname: Giannini
authors.forename: A
authors.initials: A
authors.lastname: Cataldi
authors.forename: F
authors.initials: F
authors.lastname: Botta
authors.forename: A
authors.initials: A
authors.lastname: Fasoli
authors.forename: P
authors.initials: P
authors.lastname: Tenerelli
authors.forename: E
authors.initials: E
authors.lastname: Rolandi
authors.forename: T
authors.initials: T
authors.lastname: Barreca
mesh_terms: D000273:Adipose Tissue / Q000473:pathology; D000328:Adult; D005260:Female; D019694:Hepatitis B, Chronic / Q000097:blood* / Q000150:complications / Q000473:pathology; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000150:complications / Q000473:pathology; D006801:Humans; D020738:Leptin / Q000097:blood*; D008012:Lidocaine / Q000031:analogs & derivatives* / Q000097:blood; D008103:Liver Cirrhosis / Q000097:blood* / Q000473:pathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D012016:Reference Values
chemical_list: D020738:Leptin; D008012:Lidocaine; C001173:monoethylglycinexylidide